journal article·2013-09-06

Crystalline Calcium Alendronate Obtained by Octacalcium Phosphate Digestion: A New Chance for Local Treatment of Bone Loss Diseases?

Elisa Boanini, Paola Torricelli, Massimo Gazzano, Milena Fini, Adriana Bigi

Advanced Materials· Volume 25· Issue 33
Publisher page

Abstract

Octacalcium phosphate (OCP) interaction with alendronate (AL) solution results in the complete digestion of OCP: calcium ion is recruited by the bisphosphonate to yield quantitative precipitation of crystalline calcium alendronate monohydrate. This compound improves osteoblast differentiation and inhibits osteoclast proliferation and activity, both alone and, even more, in combination with OCP. As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Bone health and treatments · Radiopharmaceutical Chemistry and Applications · Bone Metabolism and Diseases

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (37)

Show source-provided references
1. 10.1126/science.165.3899.126210.1126/science.165.3899.1262 ↗
2. 10.1007/BF0219619910.1007/BF02196199 ↗
3. 10.1016/j.bone.2011.04.02210.1016/j.bone.2011.04.022 ↗
4. 10.1007/s00198-007-0540-810.1007/s00198-007-0540-8 ↗
5. 10.1016/j.bone.2005.05.00310.1016/j.bone.2005.05.003 ↗
6. 10.1016/S0022-3565(24)38786-510.1016/S0022-3565(24)38786-5 ↗
7. 10.1016/j.bone.2011.03.77410.1016/j.bone.2011.03.774 ↗
8. 10.1089/jir.2005.25.14410.1089/jir.2005.25.144 ↗
9. 10.1016/j.bone.2011.01.00310.1016/j.bone.2011.01.003 ↗
10. 10.1016/j.biomaterials.2009.07.06610.1016/j.biomaterials.2009.07.066 ↗
11. 10.1016/j.actbio.2010.09.01710.1016/j.actbio.2010.09.017 ↗
12. 10.1016/j.jinorgbio.2010.06.00810.1016/j.jinorgbio.2010.06.008 ↗
13. 10.1021/cm702584d10.1021/cm702584d ↗
14. 10.1016/j.biomaterials.2011.09.09210.1016/j.biomaterials.2011.09.092 ↗
15. 10.1021/ja075994910.1021/ja0759949 ↗
16. 10.1021/ja902895p10.1021/ja902895p ↗
17. 10.1016/j.biomaterials.2004.05.01910.1016/j.biomaterials.2004.05.019 ↗
18. 10.1039/b503680a10.1039/b503680a ↗
19. 10.1088/1748-6041/7/5/05410810.1088/1748-6041/7/5/054108 ↗
20. 10.1016/j.bone.2007.05.00810.1016/j.bone.2007.05.008 ↗
21. 10.1016/j.bone.2010.07.01810.1016/j.bone.2010.07.018 ↗
22. 10.1016/j.bone.2012.07.02010.1016/j.bone.2012.07.020 ↗
23. 10.1002/adma.20060249710.1002/adma.200602497 ↗
24. G. S.Brenner D.Ostovic Use of bisphosphonic acids for the treatment of calcium metabolism disorders. 1991: EP 0449405.A2
25. 10.3109/0363904950902666510.3109/03639049509026665 ↗
26. Fernandez D. · Acta Cryst. · 2003 · 59 · m54310.1107/S0108768103002167 ↗
27. 10.1080/1042650950802793010.1080/10426509508027930 ↗
28. 10.22203/eCM.v024a0110.22203/eCM.v024a01 ↗
29. 10.1016/j.bbrc.2007.11.12010.1016/j.bbrc.2007.11.120 ↗
30. 10.1016/S8756-3282(99)00210-010.1016/S8756-3282(99)00210-0 ↗
31. 10.1089/ten.tea.2009.006510.1089/ten.tea.2009.0065 ↗
32. 10.1007/s00784-010-0477-810.1007/s00784-010-0477-8 ↗
33. 10.1002/jbm.a.3095010.1002/jbm.a.30950 ↗
34. 10.1016/j.biomaterials.2007.10.04010.1016/j.biomaterials.2007.10.040 ↗
35. 10.1016/j.bone.2012.12.04410.1016/j.bone.2012.12.044 ↗
36. 10.1007/s00223-011-9530-010.1007/s00223-011-9530-0 ↗
37. 10.1021/cg100494f10.1021/cg100494f ↗